Literature DB >> 8424405

The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of Merkel cell carcinoma.

E Fenig1, H Lurie, A Sulkes.   

Abstract

Five patients with advanced Merkel cell carcinoma (MCC) are described. Four patients with regional lymph node involvement and one with disseminated skin metastases were treated with systemic chemotherapy, including cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). The patients received a median of six cycles of CMF (range: 2 to 6), and chemotherapy was well tolerated. Four complete and one partial response were noted. Three patients are alive and are disease-free at 5, 12, and 37 months from the onset of CMF chemotherapy. Two patients died from disseminated metastatic disease at 3 and 24 months from the onset of chemotherapy. CMF chemotherapy appears to be an active regimen in the treatment of locally advanced MCC. Further experience with this combination is warranted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424405     DOI: 10.1097/00000421-199302000-00014

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  [Merkel cell carcinoma of the upper lid].

Authors:  W Schmitt; U Ramp
Journal:  Mund Kiefer Gesichtschir       Date:  2006-11

2.  A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).

Authors:  Wolfram E Samlowski; James Moon; Ralph J Tuthill; Michael C Heinrich; Naomi S Balzer-Haas; Stuart A Merl; Ronald C DeConti; John A Thompson; Merle T Witter; Lawrence E Flaherty; Vernon K Sondak
Journal:  Am J Clin Oncol       Date:  2010-10       Impact factor: 2.339

3.  A practical update of surgical management of merkel cell carcinoma of the skin.

Authors:  Patricia Tai
Journal:  ISRN Surg       Date:  2013-01-30

Review 4.  Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Authors:  Paul Nghiem; Howard L Kaufman; Murtuza Bharmal; Lisa Mahnke; Hemant Phatak; Jürgen C Becker
Journal:  Future Oncol       Date:  2017-03-28       Impact factor: 3.404

5.  Merkel cell carcinoma.

Authors:  Virve Koljonen
Journal:  World J Surg Oncol       Date:  2006-02-08       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.